Poster
# 15

Main Page

6th Internet World Congress for Biomedical Sciences

IndexIndex
Multi-page version
Dynamic pages

Intraarticular Synovial Sarcoma

Jesus Gonzalez Garcia(1), Marcial García Rojo(2), Francisco Martín Dávila(3), Rafael López Pérez(4), Margarita Delgado Portela(5), Manuel Carbajo Vicente(6)
(1)(2)(3)(4)(5)(6)Servicio de Anatomía Patológica. Complejo Hospitalario de Ciudad Real - Ciudad Real. Spain

[ABSTRACT] [INTRODUCTION] [CLINICAL FEATURES] [HISTOLOGIC AND IMMUNOPATHOLOGIC FEATURES] [FIGURES] [FIGURES-2] [FIGURES-3] [FIGURES-4] [DISCUSSION] [REFERENCES] [Discussion Board]
ABSTRACT Previous: Linear Focal Elastosis: a case report CLINICAL FEATURES
[Orthopedics & Traumatology]
Next: A low cost stereo vision system for vertebral column measures
[Pathology]
Next: REPRODUCTION TOXICOLOGY OF CADMIUM : A SCANNING ELECTRON MICROSCOPY STUDY

INTRODUCTION Top Page

We report a case of intraarticular synovial sarcoma in the right knee of a 25 years old male. He suffered, for a long time, of pain and limited joint function. Clinic exploration revealed a palpable mass at this level.

Synovial sarcoma is a morphologically well delineated neoplasm typically found in extremities of children and young adults, usually in near vicinity of articulations. Cases of intraarticular location are rare (10% of total synovial sarcomas)(1). This and the predominant monophasic fusocellular pattern of the neoplasm are the relevant points of this work.

CLINICAL FEATURES Top Page

The patient was a 25 years old male who suffered of a continuously increasing discomfort and pain on his right knee that began four years before diagnosis. Mobilization of the articulation incremented the pain at this level and a limited active and passive flexo-extension of the knee was clinically observed. At the palpation, there was noted a painful tumor on the inner aspect of the articulation.

In CT scan (Fig.1) and magnetic resonance imaging, the tumor had a soft tissue density and was placed within the anterior intercondyleal space with a close relation with the femoral condyle and adjacent synovial tissues. The neoplasm was delimited in rear sense by the crossing ligament and protruded forwardly in the prerotulian fat. Radiologically, the tumor had a well delimited although festooned contour and a homogeneous solid density with a hipodense band. The neoplasm displayed a low level of isotope uptake. There were no superficial osseous erosions.

HISTOLOGIC AND IMMUNOPATHOLOGIC FEATURES Top Page

The specimen was fixed in 10% buffered formalin and sections were stained with H&E, PAS, Giemsa, Alcian blue and reticulin. Immunohistochemically study was performed with Cytokeratin cocktail, EMA, Vimentin, S100, bcl2, CD34 and MIC2 antibodies, using standard methods.

Goss and microscopic findings

The tumor sized 5x4x3 cm. and had an irregular contour with a polilobulated and something villous joint surface with fatty tissue on the opposite surface. It had a soft consistency and a homogeneous grey-yellowish cut surface (Fig. 2 and 3).

Microscopic sections revealed a dense proliferation of fusiform cells arranged in a lightly fasciculated pattern (Fig 4a and 4b) with other more loosely cellular areas (Fig. 5a and 5b) and others high vascularized (Fig. 6). It was relatively well-delimited from peritumoral tissues (Fig. 7a, b and c). The monomorphous tumoral cells were medium-size with elongated nucleus, low nuclear atypia, inconspicuous nucleolus and a mitotic rate of 4-7/10 hpf((Fig. 8a and b)). Frequently, clefts were observed (Fig. 9) partially lined by hyperplastic synovial tissue. Numerous mast cells were found (Fig 10). Microcalcifications (Fig. 11) and storiform microscopic structures were observed focally, sometimes with a mucous PAS-D and Alcian blue positive center (Fig. 12a and b, and 13).

Immunohistochemical study

Neoplastic cells showed a strong positivity to Vimentin (Fig. 14a), bcl2 (Fig. 14b), EMA (Fig. 14c) and PCNA (Fig. 14d). Lighter reactivity was observed with Factor XIIIa (Fig. 14e) and only focally with citokeratin cocktail (CK8, 18 and 19) (Fig. 14f) and MIC2. The cells were negative to S100 protein, CD34, CD68, and muscle-specific Actin.

DISCUSSION Top Page

Synovial sarcoma is a clinic and morphologically well delineated entity representing among 6-10% of the total soft tissue sarcomas (1). They are usually located in paraarticular regions frequently in close relation with tendon sheaths and bursas. Primarily intraarticular synovial sarcomas are rare and most of the descriptions describe extraarticular tumors with a secondary intraarticular growth (2,3,4). Rare times, synovial sarcomas are found in tissues without near synovial structures, such as head and neck (specially in retrofaringeal area), oral cavity, retroperitoneum, anterior abdominal wall, mediastinum and intravascular.

Because of its similar morphologically appearance with synovyum, this neoplasm was first named as "synovioma" by Smith in 1927 (5). Later, Knox, in 1936 (6) proposed the term "synovial sarcoma" although hitherto never have been demonstrated a convincing origin in this membrane and so some authors believe that this neoplasm is actually a "carcinosarcoma"(7).

The neoplasm appears clinically as a deep but palpable painful mass in more than half of the cases, sometimes with some although not usually severe functional alterations. Other clinical symptoms are close related with anatomic position of the neoplasm, such as dysphagia and dysnea in head and neck location.

Because of its usually slow and insidiously growth, diagnosis and treatment is frequently delayed. Discomfort and pain are symptoms reported by the patients some years before diagnosis and is not unusual an erroneous diagnosis of synovitis, bursitis or arthritis.

Synovial sarcoma is a neoplasm of adolescents and young adults between 15 and 35 years old. Usually is found in extremities, in vicinity of the articulations, mainly the knee and in close relation with tendon sheaths and bursas, Primarily intraarticular tumors are rare, accounting for less of 10% of cases.

Histologically, two types are described, a biphasic synovial sarcoma in which fusocellular and epithelial component are represented and a monophasic type, usually fusocellular and much less frequently made up by epithelial cells only with scarcely biphasic areas. Also a poorly differentiated variety is recognised in which serious diagnostic problems may rise, reaching up to 20% of total synovial sarcomas (8). Meis-Kindblom subdivide this later type into three subgroups: a.- a giant cell variant; b.- a small cell variant and c.- a high grade fusocellular variant (9).

Ultrastructurally, cells with epithelial characteristics (bands of paranuclear tonofilaments, pseudoglandular luminas with microvilli, intercellular bindings as "macula adherens" and hemidesmosomes), fusiform cells reminiscent to fibroblasts, and "intermediate" cells can be recognized. Cells with paranucler bands of tonofilaments can be observed.

Immunohistochemically, neoplastic cells are strongly reactive to citokeratins not only in epithelial but also in fusiform areas. Virtually, all biphasic synovial sarcomas show reactivity to citokeratins and EMA. In monophasic fusocellular neoplasms citokeratin reactivity decrease to 60-70% and to 40% in poorly differentiated tumors. Normal or reactive synoviocytes do not express citokeratin immunoreactivity. Citokeratin panel can be a helpful diagnostic tool to separate them from other soft tissue sarcomas that can be positive to CK 8 and 18 but not usually with al CK7 and 19, citokeratins founded in synovial sarcomas (10,11,12)

There is S100 reactivity in 30-40% of synovial sarcomas. Although CD99 (MIC2) and bcl2 can be expressed, these antigens may be found in other soft tissue pathology or tumors (13,14,15,16) and so they are irrelevant for differential diagnosis panel. Synovial sarcomas are negative to CD34.

In 90-95% of cases, synovial sarcomas are related to a characteristic chromosome translocation t(X,18) (P11.2; q11.2). The point of rupture involves two SSX genes (chromosome X) and a SYT gene (chromosome 18). As a result of SSX-SYT fusion new chimeric genes appear. Each tumoral phenotype is related to a point of rupture, so monophasic neoplasms have the breakpoint within SSX2 region and biphasic ones, with extensive epithelial component, within SSX region (17,18,19).

Differential diagnosis include nodular and localized synovitis, pigmented villonodular synovitis and synovial chondromatosis. Nodular and localized synovitis may have clefts lined by cells (synoviocytes) with morphologic appearance similar to cells of synovial sarcoma but they haven´t epithelial characteristics, there are not glandular structures and cellular component is not so homogeneous than observed in synovial sarcoma, being more related to hystiocytic or stromal lineage with presence of giant multinucleated cells. Immunohistochemically, they do not express epithelial markers. Pigmented villonodular synovitis is a pathology with a more extensive involvement of the synovial membrane and, histollogically, haemorrhage, hemosiderin deposits and foamy cells can be observed. Only under a clinical point of view, synovial chondromatosis may raise diagnostic difficulties that are easily resolved wit macro and microscopic study. Differential diagnosis of monophasic synovial sarcomas must include fibrosarcomas, malignant schwannomas and leyomiosarcomas. In poorly differentiated neoplasms, lacking of biphasic pattern, differential diagnosis include carcinomas and round cell tumors such as Ewing sarcoma. Sometimes genetic study must be necessary to assure diagnosis, by detecting the characteristic synovial sarcoma translocation.

Prognostic factors related with a better prognosis include extensive osseous metaplasia and/or calcification, young age of patients, a prolonged clinical history before diagnosis (suggesting a low-aggressiveness neoplasm), distal location, a size less of 5 cm. and a mitotic index below 10 figures/10 hpf. On the contrary, a worse prognosis is related to a tumoral size more than 5 cm., a mitotic index above 10 figures/10 hpf, necrosis and dedifferentiated areas mainly if they comprise more than 20% of tumoral mass (1,20,21,22

Five and ten years survival oscillate between 25,2-62,5% and 11,2-30%, respectively. This drop on the survival rate reflects a high tendency of synovial sarcoma to develop late tumoral metastasis.

SS can recur locally or cause distant metastasis, mainly to lungs or lymph nodes. Referred lymph node metastatic rate is of 10-15% of cases. Elective treatment is local removal with broad surgical margins to avoid local recurrences, associated with radiotherapy and/or chemotherapy.

REFERENCES Top Page

  1. Franz M., Enzinger, Sharon W. Weiss.: Soft Tissue Tumors. Second edition, 1988. Mosby Company. St. Louis - Toronto - London.
  2. Christopher D. McKinney, M.D., Stacey E. MilIS, M.D., and Robert E. Fechner, M.D.: Intraarticular Synovial Sarcoma The American Journal of Surgical Pathology 1992; 16(10): 1017-1020.
  3. Fetsch JF, Meis JM.: Intra-articular synovial sarcoma [Abgstract]. Mod Pathol 1992;5:6A.
  4. Robert E. Fechner, M.D.and Stacey E. Mills, M.D.: Atlas of Tumor Pathology. Third series fascide 8: Tumors of the Bones and Joints 1993 Washington, d.c.
  5. Smith LW: Synoviomata. Am. J. Pathol 1927; (3): 355
  6. Knox LC: Synovial sarcoma: Report of three cases. Am. J. Cancer 1936; (28): 461
  7. Leader M, Patel J, Collins M, Kristin H.: Synovial sarcomas. True carcinosarcomas?. Cancer 1987;59:2096-8.
  8. Matthijs van de Rijn, M.D., Ph.D., Frederic G. Barr, M.D., Ph.D., Qun-Bin Xiong, M.D., Mike Hedges, Janet Shipley, Ph.D., and Cyril Fisher, M.D.: Poorly Differentiated Synovial Sarcoma: An Analysis of Clinical, Pathologic, and Molecular Genetic Features The American Journal Of Surgical Pathology 1999; 23(1): 106-112,
  9. Meis-Kindblom JM., Stenman G., Kindblom LG.: Differential diagnosis of small round cell tumors. Semin. Diagn. Pathol. 1996:13: 213-41.
  10. Smith TA, Machen SK, Fisher C, Goldblum JR: Usefulness of cytokeratin subsets for distinguishing monophasic synovial sarcoma from malignant peripheral nerve sheath tumor. Am. J. Clin. Pathol. 1999 Nov; 112(5):641-8
  11. Miettinen M: Keratin subsets in spindle cell sarcomas. Keratins are widespread but synovial sarcoma contains a distinctive keratin polypeptide pattern and desmoplakins. Am. J. Pathol. 138:505-513, 1991.
  12. Machen SK., Fisher C., Gautam RS., Tubbs M., Goldblum JR.: Utility of cytokeratin subsets for distinguishing poorly differentiated synovial sarcoma from peripheral primitive neuroectodermal tumour. Histopathology 1998 Dec;33(6):501-7.
  13. Miettinen M, Sarlomo-Rikala M, Kovatich AJ itied Cell-type- and tumour-type-related pattems of bcl-2 reactivity in mesenchymal cells and soft tissue tumours. Virchows Arch 1998 Sep.;433(3):255-60.
  14. Saul Suster, M.D., Cyril Fisher, M.D., F.R.C.Path., and Cesar A. Moran, M.D.: Expression of bcl-2 Oncoprotein in Benign and Malignant Spindle Cell Tumors of Soft Tissue, Skin, Serosal Surfaces, and Gastrointestinal Tract The American Journal of Surgical Pathology 1998; 22(7): 863-872.
  15. Folpe AL, Schmidt RA, Chapman D, Gown AM: Poorly differentiated synovial sarcoma: immunohistochemical distinction from primitive neuroectodermal tumors and hígh-grade malignant peripheral nerve sheath tumors. Am. J. Surg. Pathol. 1998 Jun;22(6):673-82
  16. Miettinen M, Sarlomo-Rikala M, Kovatich AJ: Cell-type- and tumour-type-related patterns of bcl-2 reactivity in mesenchymal cells and soft tissue tumours. J. Pathol 1988. Mar; 184(3): 337-9.
  17. Renwick PJ., Reeves BR., Dal Cin P, Fletcher CD, Kempski H., Sciot R., Kazmierczak B, Jani K., Sonobe H., Knight JC.: Two categories of synovial sarcoma defined by divergent chromosome translocation breakpoints in Xp 11.2, with implications for the histologic sub-classification of synovial sarcoma. Cytogenet. Cell Genet. 1995; 70(1-2):58-63.
  18. Kawai A, Woodruff J, Healey JH, Brennan MF, Antonescu CR, Ladanyi M.: SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N. Engl. J. Med. 1998 Jan 15-,338(3):153-60
  19. Clark J, Rocques Pj, Crew AJ, et al. :Identification of novel genes, SYT and SSX involved in the t(X;18)(p11.2;q11.2) translocation found in humanin human synovial sarcoma. Nat. Genet. 1994;7:5024- 8.
  20. Singer S, Baldini EH., Demetri GD., Fletcher JA., Corson JM.: Synovial sarcoma: prognostic significance of tumor size, margin of resection, and mitotic activity for survival. J. Clin. Oncol. 1996 Apr; 14(4):1201-8.
  21. Bergh P, Meis-Kindblom JM, Gherlinzoni F, Berlin O, Bacchini P, Bertoni F, Gunterberg B, Kindblom LG: Synovial sarcoma: identification of low and high risk groups. Cancer 1999, 15;85(12):2596-607
  22. Machen SK, Easley KA, Goldblum JR: Synovial sarcoma of the extremities: a clinicopathologic study of 34 cases, including semi-quantitative analysis of spindled, epithelial, and poorly differentiated areas. Am. J. Surg. Pathol. 1999, 23(3):268-75


Discussion Board
Discussion Board

Any Comment to this presentation?

[ABSTRACT] [INTRODUCTION] [CLINICAL FEATURES] [HISTOLOGIC AND IMMUNOPATHOLOGIC FEATURES] [FIGURES] [FIGURES-2] [FIGURES-3] [FIGURES-4] [DISCUSSION] [REFERENCES] [Discussion Board]

ABSTRACT Previous: Linear Focal Elastosis: a case report CLINICAL FEATURES
[Orthopedics & Traumatology]
Next: A low cost stereo vision system for vertebral column measures
[Pathology]
Next: REPRODUCTION TOXICOLOGY OF CADMIUM : A SCANNING ELECTRON MICROSCOPY STUDY
Jesus Gonzalez Garcia, Marcial García Rojo, Francisco Martín Dávila, Rafael López Pérez, Margarita Delgado Portela, Manuel Carbajo Vicente
Copyright © 1999-2000. All rights reserved.
Last update: 1/10/99